Summary： Serum sclerostin is positively associated with serum 25 hydroxyvitamin D concentration. Our preliminary studies confirmed that Qing＇e formula （QEF） could effectively increase serum 25 hy- droxyvitamin D c...Summary： Serum sclerostin is positively associated with serum 25 hydroxyvitamin D concentration. Our preliminary studies confirmed that Qing＇e formula （QEF） could effectively increase serum 25 hy- droxyvitamin D concentration in patients with postmenopausal osteoporosis （PMOP）, but the effect of supplementation with QEF on serum sclerostin is unknown. This study investigated the effects of sup- plementation of QEF on serum sclerostin levels in patients with PMOP. Totally 120 outpatients and in- patients with PMOP treated in our hospital between January and October 2012 were randomly divided into QEF＋calcium group, alfacalcidol＋calcium group, and placebo＋calcium group （n=40 each）, with a follow-up period of 2 years. The serum levels of sclerostin, 25 hydroxyvitamin D, and bone turnover markers （β-CTX, N-MID and T-PINP） at baseline and at the 6th month, 1st year, 1.5th year, and 2nd year after treatment were measured. The results showed that the levels of circulating sclerostin were in- creased significantly at the 6th month after treatment in QEF＋calcium group and alfacalcidol＋calcium group as compared with placebo＋calcium group （P〈0.05）, but there was no significant difference be- tween the former two groups （P〉0.05）. The levels of β-CTX, N-MID and T-PINP in serum were de- creased in both QEF＋calcium group and alfacalcidol＋calcium group at the 6th month after treatment, without significant difference between the two groups （P〉0.05）. BUt the levels were significantly lower than that in placebo＋calcium group （P〈0.05）. These results suggest that the mechanism by which QEF modulates bone metabolism in patients with PMOP might be related with the effect of QEF in increas- ing sclerostin expression. Our findings provide a scientific rationale for using QEF as an effective drug to prevent bone loss in PMOP.展开更多
Objectives: To study the partial mechanism of treating postmenopausal osteoporosis patients (POPs) using the ancient recipe of Qing’E Formula (QEF) by observing its effects on bone metabolic markers and VDR mRNA expr...Objectives: To study the partial mechanism of treating postmenopausal osteoporosis patients (POPs) using the ancient recipe of Qing’E Formula (QEF) by observing its effects on bone metabolic markers and VDR mRNA expression in primary POPs. Methods: Analysis was performed on 120 outpatient and inpatient POPs treated in our hospital between January and October 2013, where the patients were randomly divided into Qing’E group (QEF + Caltrate), Calcitriol group (Caltrate + Calcitriol soft capsules), and Compare group (Caltrate), each with a follow-up period of 1 year. Statistical analysis was then performed on bone mineral density, blood bone metabolic markers (β-CTX, N-MID, T-PINP) and changes in VDR mRNA expressions in the POPs before and after the treatments. Results: Prior to the treatments, bone mineral density and blood β-CTX, N-MID, T-PINP and VDR mRNA expression in the 3 groups of POPs exhibited no statistically significant differences, and the blood β-CTX, N-MID, T-PINP and VDR mRNA expression in the control group showed no statistically significant differences before and after the treatments. There were no significant differences in bone mineral density in the Qing’E group and the Calcitriol group before and after the treatments whereas the bone mineral density decreased in the control group after the treatments. As for blood β-CTX, N-MID, T-PINP and VDR mRNA expression, the measurements in POPs in the Qing’E group and the Calcitriol group were significantly higher than that of the control group. Conclusion: By adjusting the VDR mRNA expression, the QEF, a kidney-invigorating Chinese herbal formula, is capable of activating bone metabolism to prohibit further losses of bone mass, thereby preventing the deterioration of osteoporosis.展开更多
BACKGROUND No guideline recommends antiviral therapy for hepatitis B e antigen(HBeAg)-positive chronic hepatitis B patients with persistently normal alanine aminotransferase levels and a high hepatitis B virus(HBV)DNA...BACKGROUND No guideline recommends antiviral therapy for hepatitis B e antigen(HBeAg)-positive chronic hepatitis B patients with persistently normal alanine aminotransferase levels and a high hepatitis B virus(HBV)DNA viral load.AIM To evaluate the feasibility and safety of a Chinese herbal formula as a therapeutic option for chronic HBV infection.METHODS In total,395 patients(30–65 years old)with confirmed HBeAg-positive chronic hepatitis B infection and persistently normal alanine aminotransferase were randomized to receive either Chinese herbal formula or placebo for 96 wk.Endpoints to evaluate therapeutic efficacy included:(1)HBV DNA levels decreased to less than 4 log10 IU/mL at weeks 48 and 96;and(2)HBeAg clearance and seroconversion rates at weeks 48 and 96.RESULTS HBV DNA levels≤4 log10 IU/mL were 10.05%at week 48 and 18.59%at week 96 in the treatment group.The HBeAg clearance and conversion rates were 8.54%and 8.04%at week 48 and 16.08%and 14.57%at week 96,respectively.However,HBV DNA levels≤4 log10 IU/mL were 2.55%and 2.55%at weeks 48 and 96,respectively,and the HBeAg clearance rates were 3.06%and 5.61%at weeks 48 and 96,respectively,in the control group.The quantitative hepatitis B surface antigen and HBeAg levels at baseline and changes during the treatment period as well as the alanine aminotransferase elevation at weeks 12 and 24 were strong predictors of HBeAg clearance.CONCLUSION High rates of HBV DNA reduction,HBeAg clearance and seroconversion could be achieved with Chinese herbal formula treatments,and the treatments were relatively safe for HBeAg-positive chronic hepatitis B-infected patients with persistently normal alanine aminotransferase.The ability of the compound to modulate host immune function probably contributed to this effect.展开更多
Background: Compromised circulatory and bone/lipid metabolic dysfunction are two major contributors to non-traumatic osteonecrosis of the femoral head (ONFH). Qing’e pill plus Salvia has significant anti-inflammatory...Background: Compromised circulatory and bone/lipid metabolic dysfunction are two major contributors to non-traumatic osteonecrosis of the femoral head (ONFH). Qing’e pill plus Salvia has significant anti-inflammatory and anti-atherosclerotic action, and it could also regulate bone formation and remodeling by suppressing osteoclasts. Case Report: We describe a case of a 62-year- old man with ONFH of idiopathic type in earlier stage that could not be adequately controlled with oral non-steroidal analgesics and restoring bone loss agents for past 3 years. After six months treatment with Qing’e pill plus Salvia, the plasma low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A1 (apo A1), apolipoprotein B (apo B), total cholesterol (TC), triglycerides (TG), and blood viscosity were measured on an empty stomach. The Harris scores were maintained during a six months follow-up after discontinuation of Qing’e pill plus Salvia. Discussion: Our case has shown that plasma levels of inflammatory and atherosclerotic relaxed factors and the Harris scores may be controlled with herbal medication in ONFH of idiopathic type in earlier stage that could not be adequately controlled with oral non-steroidal analgesics and restoring bone loss agents.展开更多
基金supported by grants from Innovation Fund of Huazhong University of Science and Technology(No.2013QN235)National Natural Science Foundation of China(Nos.81403257,81473492,81102692 and 81072943)
文摘Summary： Serum sclerostin is positively associated with serum 25 hydroxyvitamin D concentration. Our preliminary studies confirmed that Qing＇e formula （QEF） could effectively increase serum 25 hy- droxyvitamin D concentration in patients with postmenopausal osteoporosis （PMOP）, but the effect of supplementation with QEF on serum sclerostin is unknown. This study investigated the effects of sup- plementation of QEF on serum sclerostin levels in patients with PMOP. Totally 120 outpatients and in- patients with PMOP treated in our hospital between January and October 2012 were randomly divided into QEF＋calcium group, alfacalcidol＋calcium group, and placebo＋calcium group （n=40 each）, with a follow-up period of 2 years. The serum levels of sclerostin, 25 hydroxyvitamin D, and bone turnover markers （β-CTX, N-MID and T-PINP） at baseline and at the 6th month, 1st year, 1.5th year, and 2nd year after treatment were measured. The results showed that the levels of circulating sclerostin were in- creased significantly at the 6th month after treatment in QEF＋calcium group and alfacalcidol＋calcium group as compared with placebo＋calcium group （P〈0.05）, but there was no significant difference be- tween the former two groups （P〉0.05）. The levels of β-CTX, N-MID and T-PINP in serum were de- creased in both QEF＋calcium group and alfacalcidol＋calcium group at the 6th month after treatment, without significant difference between the two groups （P〉0.05）. BUt the levels were significantly lower than that in placebo＋calcium group （P〈0.05）. These results suggest that the mechanism by which QEF modulates bone metabolism in patients with PMOP might be related with the effect of QEF in increas- ing sclerostin expression. Our findings provide a scientific rationale for using QEF as an effective drug to prevent bone loss in PMOP.
文摘Objectives: To study the partial mechanism of treating postmenopausal osteoporosis patients (POPs) using the ancient recipe of Qing’E Formula (QEF) by observing its effects on bone metabolic markers and VDR mRNA expression in primary POPs. Methods: Analysis was performed on 120 outpatient and inpatient POPs treated in our hospital between January and October 2013, where the patients were randomly divided into Qing’E group (QEF + Caltrate), Calcitriol group (Caltrate + Calcitriol soft capsules), and Compare group (Caltrate), each with a follow-up period of 1 year. Statistical analysis was then performed on bone mineral density, blood bone metabolic markers (β-CTX, N-MID, T-PINP) and changes in VDR mRNA expressions in the POPs before and after the treatments. Results: Prior to the treatments, bone mineral density and blood β-CTX, N-MID, T-PINP and VDR mRNA expression in the 3 groups of POPs exhibited no statistically significant differences, and the blood β-CTX, N-MID, T-PINP and VDR mRNA expression in the control group showed no statistically significant differences before and after the treatments. There were no significant differences in bone mineral density in the Qing’E group and the Calcitriol group before and after the treatments whereas the bone mineral density decreased in the control group after the treatments. As for blood β-CTX, N-MID, T-PINP and VDR mRNA expression, the measurements in POPs in the Qing’E group and the Calcitriol group were significantly higher than that of the control group. Conclusion: By adjusting the VDR mRNA expression, the QEF, a kidney-invigorating Chinese herbal formula, is capable of activating bone metabolism to prohibit further losses of bone mass, thereby preventing the deterioration of osteoporosis.
基金Supported by the National Natural Science Foundation of China,No.81174263National Science and Technology Major Project during the 12th Five-year Plan Period,No.2012ZX1005006+1 种基金Sanming Project of Medicine in Shenzhen,Guangdong Province,China,No.SZSM201612074and Science and Technology Planning Project of Guangdong Province,China,No.2017A020213016.
文摘BACKGROUND No guideline recommends antiviral therapy for hepatitis B e antigen(HBeAg)-positive chronic hepatitis B patients with persistently normal alanine aminotransferase levels and a high hepatitis B virus(HBV)DNA viral load.AIM To evaluate the feasibility and safety of a Chinese herbal formula as a therapeutic option for chronic HBV infection.METHODS In total,395 patients(30–65 years old)with confirmed HBeAg-positive chronic hepatitis B infection and persistently normal alanine aminotransferase were randomized to receive either Chinese herbal formula or placebo for 96 wk.Endpoints to evaluate therapeutic efficacy included:(1)HBV DNA levels decreased to less than 4 log10 IU/mL at weeks 48 and 96;and(2)HBeAg clearance and seroconversion rates at weeks 48 and 96.RESULTS HBV DNA levels≤4 log10 IU/mL were 10.05%at week 48 and 18.59%at week 96 in the treatment group.The HBeAg clearance and conversion rates were 8.54%and 8.04%at week 48 and 16.08%and 14.57%at week 96,respectively.However,HBV DNA levels≤4 log10 IU/mL were 2.55%and 2.55%at weeks 48 and 96,respectively,and the HBeAg clearance rates were 3.06%and 5.61%at weeks 48 and 96,respectively,in the control group.The quantitative hepatitis B surface antigen and HBeAg levels at baseline and changes during the treatment period as well as the alanine aminotransferase elevation at weeks 12 and 24 were strong predictors of HBeAg clearance.CONCLUSION High rates of HBV DNA reduction,HBeAg clearance and seroconversion could be achieved with Chinese herbal formula treatments,and the treatments were relatively safe for HBeAg-positive chronic hepatitis B-infected patients with persistently normal alanine aminotransferase.The ability of the compound to modulate host immune function probably contributed to this effect.
文摘Background: Compromised circulatory and bone/lipid metabolic dysfunction are two major contributors to non-traumatic osteonecrosis of the femoral head (ONFH). Qing’e pill plus Salvia has significant anti-inflammatory and anti-atherosclerotic action, and it could also regulate bone formation and remodeling by suppressing osteoclasts. Case Report: We describe a case of a 62-year- old man with ONFH of idiopathic type in earlier stage that could not be adequately controlled with oral non-steroidal analgesics and restoring bone loss agents for past 3 years. After six months treatment with Qing’e pill plus Salvia, the plasma low-density lipoprotein (LDL), high-density lipoprotein (HDL), apolipoprotein A1 (apo A1), apolipoprotein B (apo B), total cholesterol (TC), triglycerides (TG), and blood viscosity were measured on an empty stomach. The Harris scores were maintained during a six months follow-up after discontinuation of Qing’e pill plus Salvia. Discussion: Our case has shown that plasma levels of inflammatory and atherosclerotic relaxed factors and the Harris scores may be controlled with herbal medication in ONFH of idiopathic type in earlier stage that could not be adequately controlled with oral non-steroidal analgesics and restoring bone loss agents.
